QIAGEN Partners with U.K. to Build a World-Leading Precision Medicine Campus
Manchester, England, & HILDEN, Germany - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced their strategic partnership with Health Innovation Manchester to build a precision medicine campus in Manchester, U.K. This joint effort brings together the region's entire public, academic and clinical resources to develop a world-leading genomic campus for innovation, life sciences, translational science and molecular diagnostics.
“This is a hugely important step change for Greater Manchester's already strong life sciences sector. The new health innovation campus, with QIAGEN at its heart, will support the continued growth of businesses which are driving the future shape of medicine and health care, and cement our position as a world-leader in precision medicine,” said Rowena Burns, Chair of Health Innovation Manchester and Manchester Science Partnerships. “This is precisely what Health Innovation Manchester was set up to do, and combined with our devolved health and social care system, places us in an incredibly strong position to address the health challenges of the population.”
“These partnerships leverage QIAGEN’s rich expertise in Manchester to accelerate innovation as a basis for the development of valuable molecular tests. This is a true win-win situation, bringing together QIAGEN, the global leader in Sample to Insight solutions, with important intellectual assets in the U.K. to accelerate molecular biomarker research and subsequent development of new and promising diagnostic assays,” said Peer M. Schatz, Chief Executive Officer of QIAGEN. “We expect this collaborative initiative to serve as an innovation incubator to support translating genomic biomarkers into clinical use and ultimately to yield benefits for our customers and patients everywhere who need advanced diagnostic insights.”